Erica Teichert

Biography for Erica Teichert

Erica Teichert is the associate editor of the FierceBiotech and FiercePharma publications. A San Francisco native, Erica previously interned for the Deseret News (Utah), Where Magazine (Washington, D.C.) and BYU Magazine (Utah). She has a passion for travel, ancient history and NBA basketball-especially the Cleveland Cavaliers and Utah Jazz. She is based at the FierceMarkets main office in Washington, D.C., and can be reached at eteichert@fiercemarkets.com. Follow @FierceMedDev on Twitter and find her on LinkedIn.

Articles by Erica Teichert

Prospective Alzheimer's vax homes in on amyloid delivery

Amyloid proteins are widely associated with Alzheimer's disease: the naturally-occuring protein gathers in the brain as plaque, clogging up neural functions. A graduate student at Georgia Health

Study: Vaccinating children against flu cuts ER visits

After the CDC lowered the flu shot age recommendation to include 2- to 4-year-olds in 2006, hospitals saw a drastic decline in emergency room visits for flu-like illnesses, according to a study

Study: Removing cholesterol from HIV boosts second immune response

Researchers at the Imperial College London and Johns Hopkins University have discovered a new method that prevents HIV from weakening a patient's immune system. According to their research, the

Medicago unveils new NC manufacturing plant

One year after receiving a $21 million U.S. Defense Advanced Research Projects Agency grant to develop a vaccine manufacturing facility, Medicago has opened a 97,000-square-foot plant in Research

Bionor HIV vaccine lowers viral load, ART need

Norwegian biotech Bionor Pharma has released results from a study of its therapeutic HIV vaccine, Vacc-4x. After initially planning to shelve the vaccine last October, the company is now plotting

Merck finishes animal vaccine plant overhaul

Merck ($MRK) has completed its expansion and renovation of an Elkhorn, NE, animal vaccine plant and will begin transferring researchers from its Delaware site to the newly improved facility. The

HIV envelope protein approach elicits vaccine immune response

By focusing on HIV's envelope protein and targeting immature B cells--which the virus homes in on--researchers have found a new approach for potential vax candidates. The researchers--from Duke

Cuba announces launch of world's first lung cancer vax

Cuba has commenced sales of the world's first therapeutic lung cancer vaccine this week after 25 years of research at the Center of Molecular Immunology in Havana, according to Xinhua. "The drug

Dendreon cancels GSK Provenge contract

After months of poor sales, Dendreon ($DNDN) terminated its Provenge contract with GlaxoSmithKline ($GSK). The pharma giant would have provided the cancer vaccine's antigen through 2015 as part of

Related bacterium could create viable TB vax

The current tuberculosis vaccine--bacille Calmette-Guérin (BCG)--has produced varying efficacy rates worldwide, ranging from 0% to 80%. In a new study published in Nature Medicine, however,